Advertisement
ABBV vs BMY
Which Stock Would AI Choose? AbbVie (ABBV) vs. Bristol-Myers Squibb (BMY) Stock Comparison
Key Takeaways
- AbbVie has demonstrated robust revenue growth in recent quarters, driven by its immunology blockbusters Skyrizi and Rinvoq, which have more than offset the patent-driven decline of Humira.
- Bristol-Myers Squibb is navigating a significant portfolio transition of its own, with its Growth Portfolio expanding at a double-digit pace while its Legacy Portfolio continues to face generic erosion.
- AbbVie's stock has materially outperformed BMY over the past year, supported by upward earnings guidance revisions, a growing dividend, and a relatively low beta (a measure of volatility relative to the broader market) of 0.28.
- BMY trades at a lower valuation multiple but carries higher uncertainty due to upcoming patent expirations on Eliquis and the need for pipeline execution to fill the revenue gap.
- Both companies are active acquirers and have strengthened their pipelines through strategic deals, but AbbVie's current momentum and clearer near-term growth trajectory give it an edge in most comparative metrics.
- Dividend investors may find both stocks attractive, though AbbVie's track record as a Dividend Aristocrat and its recent 5.5% dividend increase reinforce its income-oriented appeal.
Introduction
AbbVie (ABBV) and Bristol-Myers Squibb (BMY) are two of the largest pharmaceutical companies traded on U.S. exchanges, each with a market capitalization in the hundreds of billions of dollars. Both firms operate at the intersection of immunology, oncology, and neuroscience, and both are actively managing the transition away from legacy blockbuster drugs toward next-generation therapies. For investors evaluating large-cap biopharma exposure, the comparison between these two names is especially relevant: they face structurally similar challenges yet have produced notably different stock market outcomes over the past year. This article provides a fact-based, side-by-side assessment of their recent performance, business positioning, and the signals that AI-driven analysis might highlight in the current environment.
ABBV Overview and Recent Performance
AbbVie, headquartered in North Chicago, Illinois, is a diversified biopharmaceutical company with leading franchises in immunology, neuroscience, oncology, aesthetics, and eye care. Over the past year, the company has delivered standout relative performance, with its stock advancing approximately 37% on a trailing twelve-month basis and reaching a market capitalization near $450 billion. Revenue growth has been fueled primarily by the immunology duo of Skyrizi and Rinvoq, which together generated well over $20 billion in combined annual sales and continue to grow at rates exceeding 30% year-over-year across multiple quarters. These two therapies have successfully compensated for the sharp decline in Humira revenues, which have fallen by more than 50% as biosimilar competition has intensified in the United States.
Beyond immunology, AbbVie's neuroscience portfolio has emerged as a significant growth contributor, with Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta all posting double-digit gains in recent quarters. The oncology segment has remained relatively stable, supported by Venclexta and newer additions such as Elahere and Epkinly. The company has also pursued an aggressive business development strategy, executing more than 30 M&A (mergers and acquisitions) transactions since early 2024, including the acquisition of Capstan Therapeutics and a licensing agreement with Gubra to enter the obesity treatment space. Notably, AbbVie recently settled patent litigation for Rinvoq, extending its U.S. exclusivity to 2037, a development that substantially de-risks the company's medium-term revenue outlook. The board has also raised the quarterly dividend by 5.5%, continuing the company's Dividend Aristocrat lineage.
BMY Overview and Recent Performance
Bristol-Myers Squibb, based in Princeton, New Jersey, is a global biopharmaceutical company with core capabilities in oncology, hematology, cardiovascular disease, immunology, and neuroscience. The company's recent financial performance reflects a tale of two portfolios: the Growth Portfolio — which includes Opdivo, Breyanzi, Camzyos, Reblozyl, Opdualag, and the newly launched schizophrenia treatment Cobenfy — has been expanding at a roughly 17% annual pace, while the Legacy Portfolio, anchored by Eliquis, Revlimid, Pomalyst, Sprycel, and Abraxane, has been contracting under the weight of generic competition and pricing pressures.
Full-year 2025 revenue came in at approximately $48.2 billion, essentially flat compared to the prior year. The company has guided for 2026 revenues in a range of $46.0 billion to $47.5 billion, reflecting anticipated further erosion in legacy products. On a more positive note, several Growth Portfolio products have posted impressive gains: Breyanzi revenue surged by more than 120% year-over-year in recent quarters, while Camzyos and Reblozyl each grew by over 30%. BMY has also been active on the dealmaking front, acquiring Orbital Therapeutics for $1.5 billion and entering into a broad strategic partnership with BioNTech. The company's cost-savings initiative has delivered $1 billion in efficiencies to date, with a further $1 billion targeted. BMY's stock has underperformed the broader pharmaceutical sector over the past year, and its forward outlook remains closely tied to the pace at which Growth Portfolio products can scale to offset the ongoing decline of the Legacy Portfolio, particularly as Eliquis faces looming patent expirations in key markets.
Trending AI Robots
In an environment where the relative trajectories of large-cap pharmaceutical stocks can shift rapidly based on clinical trial results, regulatory decisions, and patent developments, AI-driven trading tools have gained traction among investors seeking data-driven insights. Tickeron's Trending AI Robots page showcases a curated selection of the platform's hundreds of AI-powered trading bots, each designed to trade specific tickers using distinct strategies, timeframes, and risk parameters. These bots are continuously evaluated based on their real-world performance, and only those best aligned with prevailing market conditions earn a place in the Trending section. Some of the featured bots have demonstrated annualized returns in the 20% to 55% range, while others focus on capital preservation with lower volatility targets. Traders can explore bots that specialize in individual stocks, ETFs, or diversified baskets, with performance statistics and trade histories available for review. For those looking to complement traditional research with algorithmic signal generation, exploring the Trending AI Robots page may offer a practical starting point.
Head-to-Head Comparison
When comparing ABBV and BMY directly, several contrasts stand out. First, in terms of revenue growth trajectory, AbbVie is currently in a stronger position: its top line has been growing at a mid-to-high single-digit rate, and management has guided for a high single-digit compound annual growth rate (CAGR) through 2029, with no significant loss-of-exclusivity events expected for the remainder of the decade following the Rinvoq settlement. BMY, by contrast, is managing flat to slightly declining total revenues, with the Growth Portfolio not yet large enough to fully offset steep declines in its Legacy Portfolio.
Second, from a valuation perspective, BMY trades at a lower forward earnings multiple, which may appeal to deep-value investors willing to underwrite pipeline execution risk. AbbVie commands a higher multiple, reflecting its stronger near-term visibility and the market's confidence in the durability of its immunology franchise. Third, on income metrics, both stocks offer attractive dividend yields, but AbbVie's consistent annual dividend increases since its 2013 inception and its membership in the S&P Dividend Aristocrats Index give it a more established income-investor profile. Fourth, sector exposure is another differentiator: AbbVie has meaningful revenue contributions from aesthetics and eye care — segments that BMY does not participate in — while BMY has a proportionally larger cardiovascular footprint through Eliquis and Camzyos.
Risk profiles also differ. AbbVie's primary risk is concentration: Skyrizi and Rinvoq represent a large and growing share of total revenue, so any regulatory or competitive disruption would have an outsized impact. BMY's risk is more structural: it must simultaneously manage the decline of roughly half its revenue base (the Legacy Portfolio) while executing flawlessly on launches and pipeline readouts. Recent weeks have seen AbbVie's stock continue to exhibit relative strength, while BMY has faced ongoing investor skepticism regarding the pace of its growth transition.
Tickeron AI Verdict
Based on observable factors — including trend consistency, revenue momentum, dividend growth, relative volatility, and the resolution of key patent uncertainties — Tickeron's AI-driven analytical framework would likely favor ABBV over BMY in the current market environment. AbbVie's demonstrated ability to grow through its post-Humira transition, the extended Rinvoq patent runway to 2037, and the breadth of its pipeline across multiple therapeutic areas contribute to a more stable and upward-trending profile. BMY's lower valuation and promising Growth Portfolio products — particularly Cobenfy, Breyanzi, and Camzyos — offer a potentially asymmetric opportunity, but the company remains in a prove-it phase where execution risk is materially higher. In probabilistic terms, the AI would likely assign a higher confidence score to the trend continuity observable in ABBV while acknowledging that BMY could close the gap if its upcoming pipeline catalysts deliver meaningfully positive data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Buy and BMY is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green whileBMY’s FA Score has 3 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- BMY’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while BMY’s TA Score has 6 bullish TA indicator(s).
- ABBV’s TA Score: 4 bullish, 5 bearish.
- BMY’s TA Score: 6 bullish, 3 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +0.99% price change this week, while BMY (@Pharmaceuticals: Major) price change was +1.65% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.61%. For the same industry, the average monthly price growth was +2.10%, and the average quarterly price growth was +4.88%.
Reported Earning Dates
ABBV is expected to report earnings on Jul 31, 2026.
BMY is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.61% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | BMY | ABBV / BMY | |
| Capitalization | 448B | 126B | 356% |
| EBITDA | 16.9B | 15B | 113% |
| Gain YTD | 15.101 | 17.887 | 84% |
| P/E Ratio | 125.94 | 17.23 | 731% |
| Revenue | 62.8B | 48.5B | 129% |
| Total Cash | N/A | N/A | - |
| Total Debt | 72.9B | 46.4B | 157% |
ABBV | BMY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 87 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 66 Overvalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 5 | 83 | |
SMR RATING 1..100 | 1 | 25 | |
PRICE GROWTH RATING 1..100 | 9 | 19 | |
P/E GROWTH RATING 1..100 | 16 | 53 | |
SEASONALITY SCORE 1..100 | 29 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (4) in the Pharmaceuticals Major industry is somewhat better than the same rating for ABBV (66). This means that BMY’s stock grew somewhat faster than ABBV’s over the last 12 months.
ABBV's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is significantly better than the same rating for BMY (83). This means that ABBV’s stock grew significantly faster than BMY’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as BMY (25). This means that ABBV’s stock grew similarly to BMY’s over the last 12 months.
ABBV's Price Growth Rating (9) in the Pharmaceuticals Major industry is in the same range as BMY (19). This means that ABBV’s stock grew similarly to BMY’s over the last 12 months.
ABBV's P/E Growth Rating (16) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (53). This means that ABBV’s stock grew somewhat faster than BMY’s over the last 12 months.
| ABBV | BMY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 39% | N/A |
| Stochastic ODDS (%) | 2 days ago 49% | 2 days ago 58% |
| Momentum ODDS (%) | 2 days ago 64% | 2 days ago 51% |
| MACD ODDS (%) | 2 days ago 43% | 2 days ago 59% |
| TrendWeek ODDS (%) | 2 days ago 62% | 2 days ago 53% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 57% |
| Advances ODDS (%) | 8 days ago 59% | 8 days ago 54% |
| Declines ODDS (%) | 11 days ago 48% | 24 days ago 55% |
| BollingerBands ODDS (%) | 2 days ago 45% | 2 days ago 49% |
| Aroon ODDS (%) | 2 days ago 66% | 2 days ago 67% |
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with BMY. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +1.43% | ||
| BMY - ABBV | 52% Loosely correlated | +1.23% | ||
| NVS - ABBV | 50% Loosely correlated | +2.00% | ||
| AMGN - ABBV | 46% Loosely correlated | +1.49% | ||
| MRK - ABBV | 45% Loosely correlated | +2.36% | ||
| JNJ - ABBV | 42% Loosely correlated | +1.42% | ||
More | ||||
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.